Increasing psychosis in a patient switched from clozaril to generic clozapine [1]

American Journal of Psychiatry

Volumn 163, Issue 4, 2006, Pages 746-

  Alvarez, Carlos A ^a   Mascarenas, Cynthia ^a   Timmerman, I V A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GENERIC DRUG; LOXAPINE;

AGED; CASE REPORT; DOSE RESPONSE; FAILURE TO THRIVE; HUMAN; LETTER; MALE; PARANOIA; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PSYCHOSIS; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MEDICATION ERROR; PHARMACOKINETICS; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; CLOZAPINE; DRUGS, GENERIC; HUMANS; LOXAPINE; MALE; MEDICATION ERRORS; SCHIZOPHRENIA, PARANOID; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 33646841503     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.4.746     Document Type: Letter

References (4)

1. Pokorny R, Finkel MJ, Robinson WT: Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res 1994; 11:1221
2. Lam YW, Ereshefsky L, Toney GB, Gonzales C: Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001; 62(suppl 5):18-22; discussion, 23-24
3. Mofsen R, Balter J: Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001; 23:1720-1731
4. Sajbel TA, Carter GW, Wiley RB: Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001; 35:281-284